 Dyslipidemias
"Dyslipidemias" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Descriptor ID |
D050171
|
| MeSH Number(s) |
C18.452.584.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dyslipidemias".
Below are MeSH descriptors whose meaning is more specific than "Dyslipidemias".
This graph shows the total number of publications written about "Dyslipidemias" by people in this website by year, and whether "Dyslipidemias" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 2 | 1 | 3 | | 2006 | 3 | 1 | 4 | | 2007 | 5 | 2 | 7 | | 2008 | 4 | 3 | 7 | | 2009 | 1 | 1 | 2 | | 2010 | 5 | 2 | 7 | | 2011 | 2 | 2 | 4 | | 2012 | 2 | 3 | 5 | | 2013 | 4 | 4 | 8 | | 2014 | 4 | 2 | 6 | | 2015 | 5 | 3 | 8 | | 2016 | 4 | 4 | 8 | | 2017 | 9 | 0 | 9 | | 2018 | 4 | 4 | 8 | | 2019 | 9 | 3 | 12 | | 2020 | 4 | 1 | 5 | | 2021 | 8 | 1 | 9 | | 2022 | 2 | 1 | 3 | | 2023 | 3 | 0 | 3 | | 2024 | 5 | 2 | 7 | | 2025 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Dyslipidemias" by people in Profiles.
-
Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, Dunbar RL, Ketchum SB, Tardif JC, Martens FMAC, Ballantyne CM, Szarek M, Mason RP. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025 Mar 04; 14(5):e038656.
-
Patel SB, Wyne KL, Afreen S, Belalcazar LM, Bird MD, Coles S, Marrs JC, Peng CC, Pulipati VP, Sultan S, Zilbermint M. American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia. Endocr Pract. 2025 Feb; 31(2):236-262.
-
Wu X, Guan F, Su C, Zhang J, Jia X, Wei Y, Huang F, Li L, Bai J, Ouyang Y, Zhang X, Wang H, He Y, Du W. [Status and epidemic trends of major chronic metabolic diseases among adult residents in 10 provinces (autonomous regions) of China in 2009-2023]. Wei Sheng Yan Jiu. 2024 Nov; 53(6):880-913.
-
Guan F, He Y, Su C, Wei Y, Zhang X, Huang F, Ouyang Y, Li L, Bai J, Jia X, Zhang J, Du W, Wang H. [Distribution and epidemic trends of chronic multimorbidity among adult residents in 10 provinces (autonomous regions)of China in 2009-2023]. Wei Sheng Yan Jiu. 2024 Nov; 53(6):887-892.
-
Lv M, Su C, Huang F, Jia X, Zhang J, Wang H, Wu X, Zhou W, Du W. Combined impact of elevated C-reactive protein levels and dyslipidemia on stroke: a CHNS prospective cohort study. Front Public Health. 2024; 12:1435004.
-
Szarek M, Reijnders E, Steg PG, Jukema JW, Schwertfeger M, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, White HD, Zeiher AM, Cobbaert C, Schwartz GG. Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES. Eur J Prev Cardiol. 2024 Aug 09; 31(10):e75-e78.
-
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG. Safety of the PCSK9 inhibitor alirocumab: insights from 47?296 patient-years of observation. Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16; 10(4):342-352.
-
Wu F, Jacobs DR, Daniels SR, K?h?nen M, Woo JG, Sinaiko AR, Viikari JSA, Bazzano LA, Steinberger J, Urbina EM, Venn AJ, Raitakari OT, Dwyer T, Juonala M, Magnussen CG. Non-High-Density Lipoprotein Cholesterol Levels From Childhood to Adulthood and Cardiovascular Disease Events. JAMA. 2024 06 04; 331(21):1834-1844.
-
Althoff KN, Stewart C, Humes E, Gerace L, Boyd C, Gebo K, Justice AC, Hyle EP, Coburn SB, Lang R, Silverberg MJ, Horberg MA, Lima VD, Gill MJ, Karris M, Rebeiro PF, Thorne J, Rich AJ, Crane H, Kitahata M, Rubtsova A, Wong C, Leng S, Marconi VC, D'Souza G, Kim HN, Napravnik S, McGinnis K, Kirk GD, Sterling TR, Moore RD, Kasaie P. The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study. PLoS Med. 2024 Jan; 21(1):e1004325.
-
Wright RS, Koenig W, Landmesser U, Leiter LA, Raal FJ, Schwartz GG, Lesogor A, Maheux P, Stratz C, Zang X, Ray KK. Safety and Tolerability of Inclisiran for?Treatment of Hypercholesterolemia in?7 Clinical Trials. J Am Coll Cardiol. 2023 12 12; 82(24):2251-2261.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|